We are live on ! Find out more
DYN icon

Dyne Therapeutics

207 hedge funds and large institutions have $1.97B invested in Dyne Therapeutics in 2025 Q3 according to their latest regulatory filings, with 39 funds opening new positions, 111 increasing their positions, 38 reducing their positions, and 27 closing their positions.

New
Increased
Maintained
Reduced
Closed

192% more repeat investments, than reductions

Existing positions increased: 111 | Existing positions reduced: 38

61% more capital invested

Capital invested by funds: $1.23B → $1.97B (+$747M)

44% more first-time investments, than exits

New positions opened: 39 | Existing positions closed: 27

17% more funds holding in top 10

Funds holding in top 10: 67 (+1)

5% more funds holding

Funds holding: 197207 (+10)

3.61% less ownership

Funds ownership: 113.15%109.54% (-3.6%)

24% less call options, than puts

Call options by funds: $2.45M | Put options by funds: $3.22M

Holders
207
Holders Change
+10
Holders Change %
+5.08%
% of All Funds
2.72%
Holding in Top 10
7
Holding in Top 10 Change
+1
Holding in Top 10 Change %
+16.67%
% of All Funds
0.09%
New
39
Increased
111
Reduced
38
Closed
27
Calls
$2.45M
Puts
$3.22M
Net Calls
-$766K
Net Calls Change
-$333K
Name Holding Trade Value Shares
Change
Change in
Stake
Janus Henderson Group
1
Janus Henderson Group
United Kingdom
$186M +$60.5M +5,307,543 +56%
Vanguard Group
2
Vanguard Group
Pennsylvania
$123M +$24.1M +2,109,257 +28%
BlackRock
3
BlackRock
New York
$122M +$17.8M +1,556,481 +19%
AVLSA
4
Atlas Venture Life Science Advisors
Massachusetts
$116M
FIS
5
FCPM III Services
Netherlands
$69.1M
Fidelity Investments
6
Fidelity Investments
Massachusetts
$68.3M +$1.24M +108,547 +2%
State Street
7
State Street
Massachusetts
$66.7M +$21.8M +1,913,239 +57%
SL
8
Siren LLC
Connecticut
$59.8M -$1.22M -107,263 -2%
TCM
9
TCG Crossover Management
California
$58.4M +$9.68M +848,484 +23%
Adage Capital Partners
10
Adage Capital Partners
Massachusetts
$45M +$4.14M +363,000 +11%
Citadel Advisors
11
Citadel Advisors
Florida
$43.2M +$28.2M +2,469,561 +262%
JP Morgan Chase
12
JP Morgan Chase
New York
$42.6M +$3.18M +278,466 +9%
AC
13
Armistice Capital
New York
$38.8M +$5.75M +504,000 +20%
Marshall Wace
14
Marshall Wace
United Kingdom
$38.1M +$29.3M +2,565,570 +573%
RI
15
RTW Investments
New York
$36.6M +$13.7M +1,200,000 +71%
Geode Capital Management
16
Geode Capital Management
Massachusetts
$36.3M +$7M +613,935 +27%
T. Rowe Price Investment Management
17
T. Rowe Price Investment Management
Maryland
$35.6M +$11.6M +1,018,832 +57%
VPC
18
Vestal Point Capital
New York
$35.1M +$23.4M +2,047,500 +281%
B
19
Braidwell
Connecticut
$34.5M -$6.19M -542,868 -17%
FLSM
20
Frazier Life Sciences Management
California
$34.4M +$13.8M +1,212,121 +80%
SVCM
21
Saturn V Capital Management
Texas
$33.8M +$13.9M +1,219,040 +84%
VC
22
Vivo Capital
California
$33.1M +$17.1M +1,500,000 +135%
LGM
23
Logos Global Management
California
$30.4M +$5.7M +500,000 +26%
O
24
OrbiMed
New York
$29.3M +$14.6M +1,282,784 +124%
VA
25
VR Adviser
New York
$27.5M

DYN Hedge Fund Activity: Q3 2025 in Review

207 of the 7,620 institutional investors tracked by Wall St. Rank reported a position in Dyne Therapeutics (DYN) for Q3 2025, worth a combined $1.97B — up 61% from $1.23B a quarter earlier.

Buyers outnumbered sellers: 39 funds opened new DYN positions and 27 closed out — a net gain of 12 holders — while 111 added to existing stakes and 38 trimmed.

The largest buyer was Janus Henderson Group, adding an estimated $60.5M. The largest seller was RA Capital Management, exiting entirely with an estimated $92.5M sold.

  • 207 institutional investors held Dyne Therapeutics (DYN) as of Q3 2025, up from 197 in Q2 2025.
  • Funds reported $1.97B of Dyne Therapeutics stock for Q3 2025, up 61% quarter-over-quarter.
  • 39 funds opened new Dyne Therapeutics positions in Q3 2025 and 27 closed out, a net change of +12 holders.
  • The largest Dyne Therapeutics buyer in Q3 2025 was Janus Henderson Group, an estimated $60.5M added.
  • The largest Dyne Therapeutics seller in Q3 2025 was RA Capital Management, an estimated $92.5M sold.

Based on aggregated 13F filings for Q3 2025.